ALVR has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ALVR has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
AlloVir has the Growth Rank of 0.
GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability, rated on a scale from 1 to 10. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:
1. 5-year revenue growth rate, the higher, the better.A higher score reflects a greater ability to drive business growth, with companies considered to have strong and sustainable expansion potential. Conversely, a lower score indicates challenges in achieving consistent growth and scalability.
GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.
Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.
Thank you for viewing the detailed overview of AlloVir's Growth Rank provided by GuruFocus.com. Please click on the following links to see related term pages.
Vikas Sinha | director, 10 percent owner, officer: See Remarks | C/O ALEXION PHARMACUETICALS, INC., 352 KNOTTER DRIVE, CHESHIRE CT 06410 |
Edward Miller | officer: General Counsel | C/O ALEXION PHARMACEUTICALS, INC, 352 KNOTTER DRIVE, CHESHIRE CT 06410 |
Brett R Hagen | officer: Chief Accounting Officer | 200 TECHNOLOGY SQUARE, 4TH FLOOR, CAMBRIDGE MA 02139 |
Diana Brainard | director | C/O ALLOVIR, INC., 139 MAIN STREET, SUITE 500, CAMBRIDGE MA 02142 |
Gilead Sciences Inc | 10 percent owner | 333 LAKESIDE DR, FOSTER CITY CA 94404 |
Cintia Piccina | officer: Chief Commercial Officer | 60 JUBILEE AVENUE, MILTON PARK, ABINGDON, OXFORDSHIRE X0 X0 OX14 4R |
Derek N. Adams | director | ALLOVIR, INC., 1100 WINTER STREET, WALTHAM MA 02451 |
Van Beek Jeroen B | officer: Chief Commercial Officer | C/O TRICIDA, INC., 7000 SHORELINE COURT, SUITE 201, SOUTH SAN FRANCISCO CA 94080 |
Ercem Atillasoy | officer: See Remarks | C/O ALLOVIR, INC., 139 MAIN STREET, SUITE 500, CAMBRIDGE MA 02142 |
David Hallal | director, 10 percent owner, officer: Chief Executive Officer | C/O ALEXION PHARMACEUTICALS, INC, 352 KNOTTER DRIVE, CHESHIRE CT 06410 |
F2 - Tpo Investments Llc | director, 10 percent owner | C/O SINGER, MCKEON INC., 8 W 38TH ST SUITE 1001, NEW YORK NY 10018 |
F2 Bioscience Av 2022 Llc | director, 10 percent owner | 8 WEST 38TH STREET, SUITE 1001, NEW YORK NY 10018 |
Capital I 2020 F2 | director, 10 percent owner | 8 WEST 38TH STREET, SUITE 1001, NEW YORK NY 10018 |
F2 Mc, Llc | director, 10 percent owner | 8 WEST 38TH STREET, SUITE 1001, NEW YORK NY 10018 |
Globeways Holdings Ii Ltd | director, 10 percent owner | C/O SINGER, MCKEON INC., 8 W 38TH ST. STE. 1001, NEW YORK NY 10018 |
From GuruFocus
By PRNewswire • 03-03-2025
By PRNewswire • 11-12-2024
By PRNewswire • 11-21-2024
By Business Wire • 11-08-2024
By PRNewswire • 02-10-2025
By PRNewswire • 11-08-2024
By PRNewswire • 12-10-2024
By PRNewswire • 01-22-2025
By Marketwired • 12-04-2024
By Business Wire • 11-08-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.